Fingerprint
Dive into the research topics of 'Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically